Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
27
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Harshbarger Benjamin | Senior VP, General Counsel | 3 | $0 | $0 | 2021-06-08 |
| Callori Fred | Director | 3 | $0 | $0 | 2021-06-02 |
| Clauser Noah | Principal Financial Officer | 3 | $0 | $0 | 2021-06-02 |
| Komjathy Andrew | Chief Commercial Officer | 3 | $0 | $0 | 2021-06-02 |
| Beck Joanne T. | Director | 3 | $0 | $0 | 2021-06-02 |
| Violin Jonathan | Director | 2 | $0 | $0 | 2021-06-02 |
| Nichols Andrew John | Chief Scientific Officer | 7 | $0 | $0 | 2021-06-02 |
| Milne Jill C. | President and CEO | 14 | $0 | $0 | 2021-06-02 |
| Cole Hugh M | Director | 3 | $0 | $0 | 2021-06-02 |
| LAPOINTE ANTHONY GREGG | Director | 5 | $0 | $0 | 2021-06-02 |
| BATE KENNETH | Director | 7 | $0 | $0 | 2021-06-02 |
| KISHBAUCH MICHAEL D | Director | 6 | $0 | $0 | 2021-06-02 |
| EDELMAN JOSEPH | Director, 10% Owner | 2 | $0 | $0 | 2021-02-01 |
| ADELMAN BURT A | Director | 5 | $0 | $0 | 2020-06-11 |
| Donovan Joanne M. | Chief Medical Officer | 10 | $0 | $0 | 2020-02-12 |
| Cunnane Deirdre A. | SVP, General Counsel | 7 | $0 | $0 | 2019-02-13 |
| George Jean | Director | 15 | $3.11M | $0 | 2018-06-07 |
| Ross Michael Jay | Director | 4 | $0 | $0 | 2018-06-07 |
| Hibben Edward K. | Chief Business Officer | 1 | $0 | $0 | 2018-02-08 |
| Modi Rick | Chief Business Officer | 5 | $0 | $0 | 2016-09-08 |
| GALAKATOS NICHOLAS | Director, 10% Owner | 7 | $4.52M | $0 | 2016-08-03 |
| Sanderson Ian C. | Chief Financial Officer | 1 | $0 | $0 | 2016-02-11 |
| Laufer Ron | Director, 10% Owner | 6 | $2.68M | $0 | 2015-06-30 |
| SVLSF V, LLC | 10% Owner | 10 | $4.69M | $0 | 2015-06-30 |
| Clarus Ventures II GP, L.P. | 10% Owner | 5 | $4.52M | $0 | 2015-06-30 |
| Jirousek Michael | Chief Scientific Officer | 4 | $0 | $0 | 2015-06-30 |
| MedImmune Ventures, Inc. | 10% Owner | 5 | $2.68M | $0 | 2015-06-30 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Harshbarger Benjamin | Chief Legal Officer | A Award deriv | 2021-06-08 | 2021-06-10 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Harshbarger Benjamin | Senior VP, General Counsel | A Award deriv | 2021-06-02 | 2021-06-02 | 400,000 | — | $0 | 400,000 | SEC↗ |
| LAPOINTE ANTHONY GREGG | Director | A Award deriv | 2021-06-02 | 2021-06-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Cole Hugh M | Director | A Award deriv | 2021-06-02 | 2021-06-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2021-06-02 | 2021-06-02 | 1,400,000 | — | $0 | 1,400,000 | SEC↗ |
| Beck Joanne T. | Director | A Award deriv | 2021-06-02 | 2021-06-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| BATE KENNETH | Director | A Award deriv | 2021-06-02 | 2021-06-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| KISHBAUCH MICHAEL D | Director | A Award deriv | 2021-06-02 | 2021-06-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Clauser Noah | Chief Financial Officer | A Award deriv | 2021-06-02 | 2021-06-02 | 600,000 | — | $0 | 600,000 | SEC↗ |
| Violin Jonathan | Director | A Award deriv | 2021-06-02 | 2021-06-02 | 85,000 | — | $0 | 85,000 | SEC↗ |
| Callori Fred | Director | A Award deriv | 2021-06-02 | 2021-06-02 | 85,000 | — | $0 | 85,000 | SEC↗ |
| Nichols Andrew John | Chief Scientific Officer | A Award deriv | 2021-06-02 | 2021-06-02 | 600,000 | — | $0 | 600,000 | SEC↗ |
| Komjathy Andrew | Chief Commercial Officer | A Award deriv | 2021-06-02 | 2021-06-02 | 600,000 | — | $0 | 600,000 | SEC↗ |
| Callori Fred | Director | A Award deriv | 2021-02-01 | 2021-02-03 | 1,617 | $3009.53 | $4.87M | 30,920 | SEC↗ |
| EDELMAN JOSEPH | Director, 10% Owner | A Award deriv | 2021-02-01 | 2021-02-03 | 4,851 | $3009.53 | $14.60M | 4,851 | SEC↗ |
| EDELMAN JOSEPH | Director, 10% Owner | A Award deriv | 2021-02-01 | 2021-02-03 | 1,617 | $3009.53 | $4.87M | 30,920 | SEC↗ |
| Callori Fred | Director | A Award deriv | 2021-01-28 | 2021-02-01 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Violin Jonathan | Director | A Award deriv | 2021-01-28 | 2021-02-01 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Clauser Noah | Chief Financial Officer | A Award deriv | 2020-09-17 | 2020-09-21 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Beck Joanne T. | Director | A Award deriv | 2020-06-11 | 2020-06-12 | 7,500 | — | $0 | 7,500 | SEC↗ |
| BATE KENNETH | Director | A Award deriv | 2020-06-11 | 2020-06-12 | 7,500 | — | $0 | 7,500 | SEC↗ |
| ADELMAN BURT A | Director | A Award deriv | 2020-06-11 | 2020-06-12 | 7,500 | — | $0 | 7,500 | SEC↗ |
| LAPOINTE ANTHONY GREGG | Director | A Award deriv | 2020-06-11 | 2020-06-12 | 7,500 | — | $0 | 7,500 | SEC↗ |
| KISHBAUCH MICHAEL D | Director | A Award deriv | 2020-06-11 | 2020-06-12 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Harshbarger Benjamin | Secretary and General Counse | A Award deriv | 2020-06-11 | 2020-06-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Cole Hugh M | Director | A Award deriv | 2020-06-11 | 2020-06-12 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2020-02-12 | 2020-02-14 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Komjathy Andrew | Chief Commercial Officer | A Award deriv | 2020-02-12 | 2020-02-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Nichols Andrew John | Chief Scientific Officer | A Award deriv | 2020-02-12 | 2020-02-14 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Clauser Noah | Principal Financial Officer | A Award deriv | 2020-02-12 | 2020-02-14 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Donovan Joanne M. | CMO; SVP Clinical Developmen | A Award deriv | 2020-02-12 | 2020-02-14 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Komjathy Andrew | Chief Commercial Officer | A Award deriv | 2019-09-18 | 2019-09-19 | 44,500 | — | $0 | 44,500 | SEC↗ |
| Cole Hugh M | Director | A Award deriv | 2019-07-26 | 2019-07-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| BATE KENNETH | Director | A Award deriv | 2019-06-04 | 2019-06-05 | 7,500 | — | $0 | 7,500 | SEC↗ |
| ADELMAN BURT A | Director | A Award deriv | 2019-06-04 | 2019-06-05 | 7,500 | — | $0 | 7,500 | SEC↗ |
| KISHBAUCH MICHAEL D | Director | A Award deriv | 2019-06-04 | 2019-06-05 | 7,500 | — | $0 | 7,500 | SEC↗ |
| Beck Joanne T. | Director | A Award deriv | 2019-02-13 | 2019-02-15 | 15,000 | — | $0 | 15,000 | SEC↗ |
| LAPOINTE ANTHONY GREGG | Director | A Award deriv | 2019-02-13 | 2019-02-15 | 12,200 | — | $0 | 12,200 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2019-02-13 | 2019-02-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Donovan Joanne M. | CMO; SVP Clinical Developmen | A Award deriv | 2019-02-13 | 2019-02-15 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Nichols Andrew John | Chief Scientific Officer | A Award deriv | 2019-02-13 | 2019-02-15 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Cunnane Deirdre A. | Chief Legal Officer | A Award deriv | 2019-02-13 | 2019-02-15 | 40,000 | — | $0 | 40,000 | SEC↗ |
| LAPOINTE ANTHONY GREGG | Director | A Award deriv | 2019-01-03 | 2019-01-04 | 2,800 | — | $0 | 2,800 | SEC↗ |
| LAPOINTE ANTHONY GREGG | Director | A Award deriv | 2019-01-03 | 2019-01-04 | 2,800 | — | $0 | 2,800 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2018-09-07 | 2018-09-11 | 230,000 | — | $0 | 230,000 | SEC↗ |
| Donovan Joanne M. | CMO; SVP Clinical Developmen | A Award deriv | 2018-09-07 | 2018-09-11 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Nichols Andrew John | Chief Scientific Officer | A Award deriv | 2018-09-07 | 2018-09-11 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Cunnane Deirdre A. | Chief Legal Officer | A Award deriv | 2018-09-07 | 2018-09-11 | 150,000 | — | $0 | 150,000 | SEC↗ |
| George Jean | Director | A Award deriv | 2018-06-07 | 2018-06-07 | 14,000 | — | $0 | 14,000 | SEC↗ |
| BATE KENNETH | Director | A Award deriv | 2018-06-07 | 2018-06-07 | 14,000 | — | $0 | 14,000 | SEC↗ |
| ADELMAN BURT A | Director | A Award deriv | 2018-06-07 | 2018-06-07 | 14,000 | — | $0 | 14,000 | SEC↗ |
| KISHBAUCH MICHAEL D | Director | A Award deriv | 2018-06-07 | 2018-06-07 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Ross Michael Jay | Director | A Award deriv | 2018-06-07 | 2018-06-07 | 14,000 | — | $0 | 14,000 | SEC↗ |
| Hibben Edward K. | Chief Business Officer | A Award deriv | 2018-02-08 | 2018-02-09 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2018-02-08 | 2018-02-09 | 230,000 | — | $0 | 230,000 | SEC↗ |
| Donovan Joanne M. | CMO; SVP Clinical Developmen | A Award deriv | 2018-02-08 | 2018-02-09 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Nichols Andrew John | Chief Scientific Officer | A Award deriv | 2018-02-08 | 2018-02-09 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Cunnane Deirdre A. | SVP, General Counsel | A Award deriv | 2018-02-08 | 2018-02-09 | 100,000 | — | $0 | 100,000 | SEC↗ |
| ROSS MICHAEL JAY | Director | A Award deriv | 2017-07-27 | 2017-07-28 | 6,500 | — | $0 | 6,500 | SEC↗ |
| George Jean | Director | A Award deriv | 2017-07-27 | 2017-07-28 | 6,500 | — | $0 | 6,500 | SEC↗ |
| KISHBAUCH MICHAEL D | Director | A Award deriv | 2017-07-27 | 2017-07-28 | 6,500 | — | $0 | 6,500 | SEC↗ |
| ADELMAN BURT A | Director | A Award deriv | 2017-07-27 | 2017-07-28 | 6,500 | — | $0 | 6,500 | SEC↗ |
| BATE KENNETH | Director | A Award deriv | 2017-07-27 | 2017-07-28 | 6,500 | — | $0 | 6,500 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2017-02-09 | 2017-02-10 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Donovan Joanne M. | CMO; SVP Clinical Developmen | A Award deriv | 2017-02-09 | 2017-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Nichols Andrew John | Chief Scientific Officer | A Award deriv | 2017-02-09 | 2017-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Cunnane Deirdre A. | SVP, General Counsel | A Award deriv | 2017-02-09 | 2017-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Nichols Andrew John | Chief Scientific Officer | A Award deriv | 2016-10-03 | 2016-10-05 | 13,000 | — | $0 | 13,000 | SEC↗ |
| Cunnane Deirdre A. | SVP, General Counsel | A Award deriv | 2016-09-08 | 2016-09-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Modi Rick | Chief Business Officer | A Award deriv | 2016-09-08 | 2016-09-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2016-09-08 | 2016-09-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Donovan Joanne M. | CMO; SVP Clinical Developmen | A Award deriv | 2016-09-08 | 2016-09-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Milne Jill C. | CEO and President | A Award deriv | 2016-09-08 | 2016-09-13 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Donovan Joanne M. | CMO; SVP Clinical Developmen | A Award deriv | 2016-09-08 | 2016-09-13 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Modi Rick | Chief Business Officer | A Award deriv | 2016-09-08 | 2016-09-13 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Cunnane Deirdre A. | SVP, General Counsel | A Award deriv | 2016-09-08 | 2016-09-13 | 45,000 | — | $0 | 45,000 | SEC↗ |
| ROSS MICHAEL JAY | Director | A Award deriv | 2016-08-03 | 2016-08-05 | 6,500 | — | $0 | 6,500 | SEC↗ |
| BATE KENNETH | Director | A Award deriv | 2016-08-03 | 2016-08-05 | 6,500 | — | $0 | 6,500 | SEC↗ |
| George Jean | Director | A Award deriv | 2016-08-03 | 2016-08-05 | 6,500 | — | $0 | 6,500 | SEC↗ |
| GALAKATOS NICHOLAS | Director | A Award deriv | 2016-08-03 | 2016-08-05 | 6,500 | — | $0 | 6,500 | SEC↗ |
| ADELMAN BURT A | Director | A Award deriv | 2016-04-05 | 2016-04-07 | 13,000 | — | $0 | 13,000 | SEC↗ |
| KISHBAUCH MICHAEL D | Director | A Award deriv | 2016-04-05 | 2016-04-07 | 13,000 | — | $0 | 13,000 | SEC↗ |
| Cunnane Deirdre A. | SVP, General Counsel | A Award deriv | 2016-02-11 | 2016-02-16 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Donovan Joanne M. | Chief Medical Officer | A Award deriv | 2016-02-11 | 2016-02-16 | 66,000 | — | $0 | 66,000 | SEC↗ |
| Modi Rick | Chief Business Officer | A Award deriv | 2016-02-11 | 2016-02-16 | 42,000 | — | $0 | 42,000 | SEC↗ |
| Sanderson Ian C. | Chief Financial Officer | A Award deriv | 2016-02-11 | 2016-02-16 | 52,000 | — | $0 | 52,000 | SEC↗ |
| Milne Jill C. | President and CEO | A Award deriv | 2016-02-11 | 2016-02-16 | 103,000 | — | $0 | 103,000 | SEC↗ |
| Milne Jill C. | President and CEO | A Award deriv | 2015-07-17 | 2015-07-21 | 160,000 | — | $0 | 160,000 | SEC↗ |
| Laufer Ron | Director, 10% Owner | A Award deriv | 2015-06-30 | 2015-06-30 | 11,094 | — | $0 | 11,094 | SEC↗ |
| Laufer Ron | Director, 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 13,866,666 | — | $0 | 0 | SEC↗ |
| Laufer Ron | Director, 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 4,241,780 | — | $0 | 0 | SEC↗ |
| MedImmune Ventures, Inc. | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 4,241,780 | — | $0 | 0 | SEC↗ |
| MedImmune Ventures, Inc. | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 13,866,666 | — | $0 | 0 | SEC↗ |
| Milne Jill C. | President and CEO | C Conversion deriv | 2015-06-30 | 2015-06-30 | 856,548 | — | $0 | 0 | SEC↗ |
| Milne Jill C. | President and CEO | C Conversion deriv | 2015-06-30 | 2015-06-30 | 105,229 | — | $0 | 0 | SEC↗ |
| Modi Rick | Chief Business Officer | C Conversion deriv | 2015-06-30 | 2015-06-30 | 52,614 | — | $0 | 0 | SEC↗ |
| ROSS MICHAEL JAY | Director | A Award deriv | 2015-06-30 | 2015-06-30 | 11,094 | — | $0 | 11,094 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 9,821,385 | — | $0 | 0 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 21,218,253 | — | $0 | 0 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 448,414 | — | $0 | 0 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 207,558 | — | $0 | 0 | SEC↗ |
| BATE KENNETH | Director | A Award deriv | 2015-06-30 | 2015-06-30 | 11,094 | — | $0 | 11,094 | SEC↗ |
| Clarus Ventures II GP, L.P. | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 9,728,971 | — | $0 | 0 | SEC↗ |
| Clarus Ventures II GP, L.P. | 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 20,800,000 | — | $0 | 0 | SEC↗ |
| Donovan Joanne M. | Chief Medical Officer | C Conversion deriv | 2015-06-30 | 2015-06-30 | 5,261 | — | $0 | 0 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | A Award deriv | 2015-06-30 | 2015-06-30 | 11,094 | — | $0 | 11,094 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 9,728,971 | — | $0 | 0 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion deriv | 2015-06-30 | 2015-06-30 | 20,800,000 | — | $0 | 0 | SEC↗ |
| George Jean | Director | C Conversion deriv | 2015-06-30 | 2015-06-30 | 8,666,667 | — | $0 | 0 | SEC↗ |
| George Jean | Director | A Award deriv | 2015-06-30 | 2015-06-30 | 11,094 | — | $0 | 11,094 | SEC↗ |
| George Jean | Director | C Conversion deriv | 2015-06-30 | 2015-06-30 | 1,006,712 | — | $0 | 0 | SEC↗ |
| George Jean | Director | C Conversion deriv | 2015-06-30 | 2015-06-30 | 7,388,491 | — | $0 | 0 | SEC↗ |
| George Jean | Director | C Conversion deriv | 2015-06-30 | 2015-06-30 | 3,910,392 | — | $0 | 0 | SEC↗ |
| Jirousek Michael | Chief Scientific Officer | C Conversion deriv | 2015-06-30 | 2015-06-30 | 5,261 | — | $0 | 0 | SEC↗ |
| Jirousek Michael | Chief Scientific Officer | C Conversion deriv | 2015-06-30 | 2015-06-30 | 856,571 | — | $0 | 0 | SEC↗ |
| Laufer Ron | Director, 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 330,098 | — | $0 | 1,409,213 | SEC↗ |
| Laufer Ron | Director, 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 1,079,115 | — | $0 | 1,079,115 | SEC↗ |
| Laufer Ron | Director, 10% Owner | P Buy | 2015-06-30 | 2015-06-30 | 223,439 | $12.00 | $2.68M | 1,632,652 | SEC↗ |
| MedImmune Ventures, Inc. | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 330,098 | — | $0 | 1,409,213 | SEC↗ |
| MedImmune Ventures, Inc. | 10% Owner | P Buy | 2015-06-30 | 2015-06-30 | 223,439 | $12.00 | $2.68M | 1,632,652 | SEC↗ |
| MedImmune Ventures, Inc. | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 1,079,115 | — | $0 | 1,079,115 | SEC↗ |
| Milne Jill C. | President and CEO | C Conversion | 2015-06-30 | 2015-06-30 | 8,189 | — | $0 | 253,872 | SEC↗ |
| Milne Jill C. | President and CEO | C Conversion | 2015-06-30 | 2015-06-30 | 66,657 | — | $0 | 245,683 | SEC↗ |
| Modi Rick | Chief Business Officer | C Conversion | 2015-06-30 | 2015-06-30 | 4,094 | — | $0 | 4,094 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 34,893 | — | $0 | 34,893 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 1,651,223 | — | $0 | 1,651,223 | SEC↗ |
| SVLSF V, LLC | 10% Owner | P Buy | 2015-06-30 | 2015-06-30 | 8,094 | $12.00 | $97.1K | 59,139 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 764,309 | — | $0 | 2,415,532 | SEC↗ |
| SVLSF V, LLC | 10% Owner | P Buy | 2015-06-30 | 2015-06-30 | 382,996 | $12.00 | $4.60M | 2,798,528 | SEC↗ |
| SVLSF V, LLC | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 16,152 | — | $0 | 51,045 | SEC↗ |
| Clarus Ventures II GP, L.P. | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 1,618,676 | — | $0 | 1,618,676 | SEC↗ |
| Clarus Ventures II GP, L.P. | 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 757,117 | — | $0 | 2,375,793 | SEC↗ |
| Clarus Ventures II GP, L.P. | 10% Owner | P Buy | 2015-06-30 | 2015-06-30 | 376,695 | $12.00 | $4.52M | 2,752,488 | SEC↗ |
| Donovan Joanne M. | Chief Medical Officer | C Conversion | 2015-06-30 | 2015-06-30 | 409 | — | $0 | 409 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | P Buy | 2015-06-30 | 2015-06-30 | 376,695 | $12.00 | $4.52M | 2,752,488 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 757,117 | — | $0 | 2,375,793 | SEC↗ |
| GALAKATOS NICHOLAS | Director, 10% Owner | C Conversion | 2015-06-30 | 2015-06-30 | 1,618,676 | — | $0 | 1,618,676 | SEC↗ |
| George Jean | Director | C Conversion | 2015-06-30 | 2015-06-30 | 574,979 | — | $0 | 574,979 | SEC↗ |
| George Jean | Director | C Conversion | 2015-06-30 | 2015-06-30 | 304,309 | — | $0 | 978,755 | SEC↗ |
| George Jean | Director | C Conversion | 2015-06-30 | 2015-06-30 | 78,342 | — | $0 | 78,342 | SEC↗ |
| George Jean | Director | P Buy | 2015-06-30 | 2015-06-30 | 155,188 | $12.00 | $1.86M | 1,133,943 | SEC↗ |
| George Jean | Director | P Buy | 2015-06-30 | 2015-06-30 | 91,166 | $12.00 | $1.09M | 666,145 | SEC↗ |
| George Jean | Director | P Buy | 2015-06-30 | 2015-06-30 | 12,422 | $12.00 | $149.1K | 90,764 | SEC↗ |
| George Jean | Director | C Conversion | 2015-06-30 | 2015-06-30 | 674,446 | — | $0 | 674,446 | SEC↗ |
| Jirousek Michael | Chief Scientific Officer | C Conversion | 2015-06-30 | 2015-06-30 | 66,658 | — | $0 | 245,684 | SEC↗ |
| Jirousek Michael | Chief Scientific Officer | C Conversion | 2015-06-30 | 2015-06-30 | 409 | — | $0 | 246,093 | SEC↗ |